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Recovery from acute hepatitis B virus (HBV) infection requires a broad, vigorous T-cell response, which is
enhanced in mice when chemokine receptor 5 (CCR5) is missing. To test the hypothesis that production of a
nonfunctional CCR5 (CCR5⌬32 [a functionally null allele containing a 32-bp deletion]) increases the likelihood of recovery from hepatitis B in humans, we studied 526 persons from three cohorts in which one person
with HBV persistence was matched to two persons who recovered from an HBV infection. Recovery or
persistence was determined prior to availability of lamivudine. We determined genotypes for CCR5⌬32 and for
polymorphisms in the CCR5 promoter and in coding regions of the neighboring genes, chemokine receptor 2
(CCR2) and chemokine receptor-like 2 (CCRL2). Allele and haplotype frequencies were compared among the
190 persons with viral recovery and the 336 with persistence by use of conditional logistic regression. CCR5⌬32
reduced the risk of developing a persistent HBV infection by nearly half (odds ratio [OR], 0.53; 95% confidence
interval [CI], 0.33 to 0.83; P ⴝ 0.006). This association was virtually identical in persons with and without a
concomitant human immunodeficiency virus infection. Of the nine individuals who were homozygous for the
deletion, eight recovered from infection (OR, 0.25; 95% CI, 0.03 to 1.99; P ⴝ 0.19). None of the other
neighboring polymorphisms examined were associated with HBV outcome. These data demonstrate a protective effect of CCR5⌬32 in recovery from an HBV infection, provide genetic epidemiological evidence for a role
of CCR5 in the immune response to HBV, and suggest a potential therapeutic treatment for patients persistently infected with HBV.
ple, CCR5-deficient mice (ccr5⫺/⫺) infected with Mycobacterium tuberculosis have more dendritic cells in lymph nodes and
increased pulmonary inflammation due to a greater T-cell response than ccr5⫹/⫹ mice (2). Similar data have been reported
for mouse models of Listeria and lymphocytic choriomeningitis
virus infections, as well as for enhanced responses to a melanoma dendritic cell vaccine (25, 26, 39). How CCR5 restrains
the immune response is unknown.
Given the importance of the T-cell response in hepatitis B
recovery and the increased T-cell response to various antigens
observed with ccr5⫺/⫺ mice, we hypothesized that humans with
CCR5⌬32 would be more likely to recover from acute hepatitis
B. We tested this hypothesis by genotyping CCR5 in a large
cohort of Caucasian HBV-infected individuals who were wellcharacterized as having either HBV recovery or persistence.

Most adults infected with hepatitis B virus (HBV) recover
and develop protective antibodies. However, approximately
5% of adults remain chronically infected with HBV and are at
risk for developing end-stage liver disease and hepatocellular
carcinoma (20). Hepatitis B recovery occurs more often in
individuals who develop a broad and strong T-cell response
than in those with weak and narrowly focused responses (28).
CCR5 (chemokine receptor 5) is a CC chemokine receptor
expressed by granulocytes, macrophages, immature dendritic
cells, CD8⫹ lymphocytes, and Th1 lymphocytes, and it influences their migration and activation (36). It has also been
identified as a coreceptor for human immunodeficiency virus
(HIV) entry into host cells (37). The CCR5 gene consists of a
single coding exon, and a functionally null allele containing a
32-bp deletion (CCR5⌬32) has been identified in 10 to 15% of
Caucasians (21). Individuals heterozygous for the deletion
(CCR5⌬32/⫹) have substantially reduced levels of CCR5 on
the cell surface compared to those who are homozygous for the
normal CCR5 allele (⫹/⫹) (38).
One consequence of CCR5 deficiency in mice is a more
robust T-cell response to several infectious agents. For exam-

MATERIALS AND METHODS
Study participants. Since CCR5⌬32 is present only in Caucasians, we studied
Caucasian persons who were participating in one of the following ongoing studies: (i) the Multicenter AIDS Cohort Study (MACS), which is a study of 5,622
gay men enrolled in one of four U.S. cities between 1984 and 1985 and between
1987 and 1991 (18), (ii) the Multicenter Hemophilia Cohort Study (MHCS), a
prospectively followed cohort of patients with hemophilia, von Willebrand’s
disease, or a related coagulation disorder from 16 comprehensive hemophilia
treatment centers enrolled between 1982 and 1986, as previously described (11),
or (iii) the Hemophilia Growth and Development Study (HGDS), which is a
continuing study of 333 children and adolescents with hemophilia enrolled be-
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TABLE 1. Distribution of CCR5⌬32 and CCR5⫺2459G promoter
variant, stratified by HBV recovery and persistence
% of alleles or subjects with
genotypea
Genotype

CCR5⌬32
CCR5⫹/⫹
⫺2459G
⫺2459GG

HBV recovery
(n ⫽ 336)

HBV persistence
(n ⫽ 190)

13.0*
76.4**
42.0*
19.1**

7.4*
85.7**
45.4*
22.0**

ORb

95% CI

P

0.53
1.95
1.14
1.23

0.33–0.83
1.18–3.23
0.88–1.48
0.77–1.96

0.006
0.009
0.34
0.38

a
*, values represent percentages of alleles (chromosomes); **, values represent percentages of subjects with genotype.
b
An odds ratio of ⬎1 is associated with viral persistence, and an odds ratio of
⬍1 is associated with viral recovery.

were inferred from the genotypes in the study population and were constructed
using a program designed for population-based studies, PHASE v 2.0 (http:
//www.stat.washington.edu/stephens/software.html) (30). A P value of ⬍0.05 was
considered significant in all analyses, and any genotype that met this criterion was
stratified by HIV status to exclude an HIV association.

RESULTS
This study included 526 Caucasian subjects who had been
infected with HBV, of whom 190 were chronically infected and
were matched to 336 individuals who had recovered from the
infection. No significant differences were detected between
cases and controls in terms of nongenetic factors, with a median age of 31.5, 100% male, and 69% HIV infected.
CCR5⌬32 is associated with recovery from HBV infection.
The overall allele frequency of CCR5⌬32 for all study subjects
was 11%, which is consistent with its known population frequency (7). CCR5⌬32 was more frequent in those subjects who
recovered from infection than in those with a persistent HBV
infection (Table 1). In fact, based on an allelic analysis,
CCR5⌬32 reduced the risk of developing a persistent hepatitis
B infection by nearly half (OR, 0.53; 95% confidence interval
[CI], 0.33 to 0.83; P ⫽ 0.006). In addition to matching cases and
controls by HIV status, we stratified the analyses by HIV status
to rule out any possibility that HIV infection could confound
our analysis; notably, CCR5⌬32 showed virtually identical levels of protection in the HIV-negative pairs and in the HIVpositive pairs (OR, 0.49 and 0.54, respectively). Of the nine
individuals who were homozygous for the deletion (CCR5⌬32/
⌬32), eight recovered from infection, suggesting strong protection against HBV persistence in the absence of functional
CCR5 molecules altogether (OR, 0.25; 95% CI, 0.03 to 1.99;
P ⫽ 0.19). Thus, CCR5⌬32 appears to have a codominant
effect on recovery in that the likelihood of recovery among
heterozygotes was intermediate compared to the likelihoods
for the CCR5⌬32/⌬32 and CCR5⫹/⫹ genotypes (Fig. 1). Viral
persistence was more common among individuals with the
CCR5⫹/⫹ genotype (OR, 1.95; 95% CI, 1.17 to 3.23; P ⫽
0.009) than among individuals with at least one copy of
CCR5⌬32.
The A⫺2459G CCR5 promoter variant (⫺2459G) has been
associated with slower AIDS progression (5) and may decrease
CCR5 transcription (23). Thus, we tested whether this promoter variant was also associated with HBV recovery. In our
study sample, the ⫺2459G variant was in complete linkage
disequilibrium with the CCR5⫹ allele and thus was never on
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tween March 1989 and May 1990 (13). The majority of the subjects were from the
MACS cohort (80%), with the HGDS and the MHCS each contributing 10%.
Informed consent was obtained from all participants.
To investigate our hypothesis, a nested case-control design was used. In this
design, each individual from one of the above-described cohorts who had a
persistent hepatitis B infection was matched to two persons from the same cohort
who recovered from an HBV infection but were otherwise similar with regard to
nongenetic factors. Matching criteria included geographic location and factors
that have been associated with HBV recovery, including age within 10 years,
gender, and HIV type 1 (HIV-1) status (16). In this study, for 44 persistently
infected persons, only one match was available. There were no persistently
infected persons included who did not have at least one match.
Subjects were considered persistently infected with HBV if their serum or
plasma tested positive for hepatitis B surface antigen (HBsAg) at two visits
separated by a minimum of 6 months. Testing for antibodies against hepatitis B
core antigen (anti-HBc) and HBsAg (anti-HBs) was performed as needed to
exclude primary HBV infection. Individuals with HBV recovery were positive
for anti-HBc and anti-HBs without the presence of HBsAg at two time points
separated by a minimum of 6 months. All initial tests were performed on
serum at the time of entry into the cohort study. HBV status of HIV-positive
subjects was determined before antiretroviral therapy (including lamivudine)
was available.
Serologic testing. All serum specimens were stored at ⫺70°C prior to testing.
HIV-1 antibody testing was done by enzyme immunoassay with reactive results
confirmed as positive by Western blotting (11, 18). HBsAg, anti-HBs, and antiHBc testing was done by using commercially available kits according to the
manufacturer’s specifications (AUSZYME, AUSAB, and CORZYME, respectively; Abbott Laboratories, Abbott Park, IL).
DNA extraction and genotyping. For each individual, Epstein-Barr virus-transformed cell lines were established, and genomic DNA was extracted from these
cell lines by use of phenol-chloroform.
CCR5⌬32 genotyping was performed using PCR amplification of genomic
DNA with primers CCR-5A, 5⬘-AGGTCTTCATTACACCTGCAGC-3⬘, and
CCR-5B, 5⬘-CCTCTCATTTCGACACCGAAGC-3⬘. The PCR products were
separated by electrophoresis in a 3% agarose gel (169 bp for the wild-type allele
and 137 bp for the 32-bp-deletion allele). CCR5 promoter polymorphism 59029
(rs1799987, CCR5-2459) was determined by restriction fragment length polymorphism as previously described (3).
To determine if the association with CCR5⌬32 was due to linkage disequilibrium with a neighboring gene, we also genotyped polymorphisms leading to
nonsynonymous changes in adjacent genes CCR2 (chemokine receptor 2) and
CCRL2 (chemokine receptor-like 2). The CCR2-64I polymorphism (rs1799864)
was defined using the Assay-by-Design service from Applied Biosystems under
conditions recommended by the manufacturer (forward primer, 5⬘-TCTTTGG
TTTTGTGGGCAACATG-3⬘; reverse primer, 5⬘-AGGTAAATGTCAGTCAA
GCACTTCA-3⬘; probe, 5⬘-TGGTCA[G]TCCTCATC-3⬘). Three CCRL2 polymorphisms, T500A (rs3204849), G502A (rs6441977), and A727G (rs3204850),
for which the minor allele at each position had a frequency of ⬎5%, were
genotyped using an AcycloPrime-FP single-nucleotide polymorphism (SNP) detection assay (Perkin Elmer, Boston, MA), a single-base extension method performed according to the manufacturer’s specifications (15). In this method, a
200-bp fragment containing the SNP of interest is amplified (primers available
upon request) with cycling conditions of 95°C for 10 min, 35 cycles of 94°C for
15 s, 55°C for 30 s, and 72°C for 60 s, and then a final extension step of 72°C for
10 min. After amplification, the excess primer and deoxynucleoside triphosphates were degraded with shrimp alkaline phosphatase and exonuclease I used
according to the manufacturer’s specifications. These enzymes are heat inactivated, allowing for the final step, which adds one of two fluorescent terminators,
representing the alleles present at the SNP of interest, to a primer ending
immediately upstream of the SNP site (extension primer). The cycling protocol
for the single base extension step is 95°C for 2 min followed by 15 cycles of 95°C
for 15 s and 55°C for 30 s. The results are identified by the amount of fluorescence polarization of each allele as determined by a Victor2V instrument (Perkin
Elmer, Boston, MA). In order to determine the accuracy of this method, we
verified the results with direct sequencing in 15 samples for each SNP and found
no errors.
All polymorphisms in this study were in Hardy-Weinberg equilibrium, which
was assessed for each SNP/deletion by using the chi-square test with 1 degree of
freedom.
Statistical analysis. Allele frequencies for CCR5⌬32 were calculated and
compared between those persons with viral recovery and persistence by use of
conditional logistic regression (SAS version 10; SAS, Cary, NC). An odds ratio
(OR) of ⬎1 was associated with persistence and ⬍1 with recovery. Haplotypes
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and OR, 0.50; 95% CI, 0.32 to 0.80; P ⫽ 0.003, respectively)
(Table 2). However, haplotype analyses indicated that these
associations were due to linkage disequilibrium with
CCR5⌬32. Haplotypes containing either the 500T or the 502A
variant without CCR5⌬32 were not associated with HBV recovery. Neither the wild type nor the variant of CCRL2 at
⫺727 was associated with HBV outcomes. Stratification by
HIV status revealed no difference between the HIV-positive
and HIV-negative subjects in these analyses.

FIG. 1. Graphic representation of odds ratios for recovery from
HBV infection based on different CCR5 genotypes. Odds ratios were
calculated using a model in which the CCR5⫹/⫹ genotype (homozygous wild type) was the reference group (set to an odds ratio of 1) and
the genotypes CCR5⌬32/⫹ (OR, 0.54; 95% CI, 0.32 to 0.90) and
CCR5⌬32/⌬32 (OR, 0.20; 95% CI, 0.03 to 1.61) were separate terms.
Odds ratios of ⬍1 favor viral recovery.

the same haplotype as CCR5⌬32. Univariate analysis did not
demonstrate a difference in allele frequency of the promoter
variant between those subjects who recovered from HBV infection and those who did not (Table 1). Similarly, homozygosity for either the variant or the wild type was not associated
with HBV outcome. A multivariate model that included
CCR5⌬32 and ⫺2459G as covariables in the analysis did not
reveal any association with the promoter variant, indicating
that the strong association of CCR5⌬32 with HBV recovery did
not mask a CCR5 promoter association.
Polymorphisms in genes neighboring CCR5⌬32 are not associated with HBV outcome. In order to ascertain whether the
association between HBV recovery and CCR5⌬32 could be
due to a neighboring locus in strong linkage disequilibrium
with CCR5⌬32, nonsynonymous SNPs within the two neighboring genes, CCR2 and CCRL2, were typed in our cohort. A
previously identified polymorphism in CCR2, which involves an
amino acid change from valine to isoleucine at position 64
(CCR2-64I), has been associated with slower progression to
AIDS, suggesting an effect on CCR2 function (29), and was
therefore genotyped in our HBV samples. Univariate analysis
of CCR2-64I revealed a trend with HBV recovery, although it
was not significant (OR, 0.72; 95% CI, 0.48 to 1.07; P ⫽ 0.11)
(Table 2). CCR2-64I was always present on a CCR5⫹ haplotype, similarly to results from previous studies (29), and thus
cannot explain the association of HBV recovery with
CCR5⌬32. To determine whether the strong association of
CCR5⌬32 with viral clearance masked an association with
CCR2-64I, we constructed a multivariate model with CCR5⌬32
and CCR2-64I as covariables. The weak association with
CCR2-64I was not strengthened under this model, nor did it
alter the CCR5⌬32 association.
The three nonsynonymous coding region polymorphisms in
CCRL2 that had frequencies of ⬎5% (T500A, G502A, and
A727G) were genotyped in a subset of subjects (n ⫽ 382). In
univariate analysis, the 500T and 502A alleles were associated
with HBV recovery (OR, 0.74; 95% CI, 0.54 to 1.00; P ⫽ 0.05

These data demonstrate a protective effect of CCR5⌬32 in
recovery from an HBV infection, which is unlikely to involve
neighboring loci in linkage disequilibrium with CCR5. We
found that individuals who have at least one copy of the gene
encoding a nonfunctional receptor (CCR5⌬32) are twice as
likely to recover from hepatitis B, and the protective effect
appears to be codominant. Based on data from ccr5⫺/⫺ mouse
models, there are at least two potential explanations for these
observations. First, several studies demonstrate that CCR5deficient mice have increased CD4⫹ and CD8⫹ T-cell responses to a variety of antigens and to a dendritic cell vaccine
(25, 26, 39). Such findings suggest that CCR5 may behave as a
negative regulator of T cells in an immune response. Data
from a cohort of hemophiliacs support this increase in T-cell
responses with CCR5 deficiency because CCR5⌬32 homozygous individuals had a 30% increase in lymphocytes compared
to CCR5⫹/⫹ individuals (27). Within the hepatitis C-infected
subgroup of these hemophiliacs, the CCR5⌬32 homozygous
individuals had a 117% increase in alanine aminotransferase, a
marker of liver inflammation, compared to levels for those
without CCR5⌬32, suggesting a greater T-cell-dependent inflammatory response among individuals with low/no CCR5.
Thus, CCR5-mediated attenuation of the immune response
may increase the risk of HBV persistence. Second, based on a

TABLE 2. Percentages of alleles with indicated CCR2 or CCRL2
polymorphisms and percentages of indicated CCRL2-CCR5
haplotypes in subjects with HBV recovery and persistence

Genotype or haplotype

% of alleles or subjects
with haplotype or
genotypea

ORb

95% CI

P

8.5*
55.8*
11.2*
6.9*

0.72
0.74
0.50
0.80

0.48–1.07
0.54–1.00
0.32–0.80
0.45–1.42

0.11
0.05
0.003
0.45

48.8**
7.3**
4.4**
7.3**

1.00
0.44
0.70
0.47

0.73–1.38
0.25–0.78
0.33–1.49
0.26–0.84

0.98
0.005
0.36
0.01

HBV
recovery

HBV
persistence

Genotype
CCR2-64I
CCRL2-500T
CCRL2-502A
CCRL2⫺727G

11.1*
62.8*
18.8*
8.2*

CCRL2-CCR5 haplotype
500T-WT c
500T-⌬32
502A-WT
502A-⌬32

48.3**
14.2**
5.8**
13.6**

a
*, values represent percentages of alleles; **, values represent percentages of
subjects with haplotype. For CCRL2 polymorphisms, there were 244 subjects
with HBV recovery and 138 with HBV persistence, since these polymorphisms
were tested only in a subset of subjects. For CCR2, there were 336 subjects with
viral recovery and 190 with viral persistence.
b
An odds ratio of ⬎1 is associated with viral persistence, and an odds ratio of
⬍1 is associated with viral recovery.
c
WT, wild-type CCR5.
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suppression. Also, the status of the HBV infection was established prior to the availability of oral antiretroviral agents with
activity against both HIV and HBV; thus, none of the individuals had been treated for HIV or HBV at the time the HBV
infection status was determined.
Even though CCR5⌬32 is associated with recovery from
HBV infection, the majority of people who recovered from
infection in this study did not have this deletion. This is expected since recovery from hepatitis B is certainly polygenic, so
CCR5⌬32 is one of several genes involved in HBV pathogenesis. Although other relevant genes have been identified previously (4, 14, 31–35), this deletion is important since it is
present in 13% of people who recovered and it has one of the
strongest odds ratios published to date.
The fact that our findings support data from mouse models
showing an increased T-cell response to other infectious agents
with CCR5 deficiency is particularly intriguing because it offers
a potential means to enhance the T-cell response to HBV by
blocking CCR5. Current therapeutic options (nucleoside [or
nucleotide] analogues) to treat chronic hepatitis B led to a
therapeutic response in only a minority of treated individuals
(8, 22). Thus, simultaneous administration of a CCR5 blocking
agent, which is already being developed for HIV infection,
along with an anti-HBV agent may increase HBV clearance
through augmentation of the T-cell response to HBV antigens.
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concanavalin A (ConA)-induced fulminant hepatitis murine
model, which is a model of T-cell-mediated hepatitis, CCR5
deficiency prevents hepatic natural killer T (NKT) cell apoptosis and upregulates NKT cell function (1), phenomena that
would favor recovery from HBV infection since NK and NKT
cells are important in controlling HBV replication in HBV
transgenic mouse models (17). A second study of ConA-induced hepatitis demonstrated that CCL5, which is the ligand
for CCR5 and is increased in CCR5 deficiency, enhanced recruitment of chemokine receptor 1 (CCR1)-expressing CD4⫹
T cells, NKT cells, and macrophages into the liver (24). These
CCR1-expressing CD4⫹ T cells produce gamma interferon
during ConA-induced hepatitis in normal mice, and if this
occurs during hepatitis B infection, it would also increase the
likelihood of recovery from hepatitis B (12). Our data also
suggest that there is a gene dosage effect, since one copy of
CCR5⌬32 was intermediate in protective effect compared to
zero and two copies; however, mice heterozygous for the ccr5
deletion have not been studied to confirm this.
Given these seemingly functional benefits of missing CCR5,
its absence may have a dual protective effect against HIV:
decreased viral entry into host cells and increased innate/acquired immunity against the virus. The latter effect may be
operative against a number of viral infections, including HBV.
On the other hand, increased susceptibility to West Nile virus
both in mice that are CCR5 deficient and in humans who have
the CCR5⌬32 allele has also been reported previously (9, 10).
Thus, CCR5 deficiency appears to impact the response to a
variety of infections in ways that are not necessarily easy to
predict, possibly due to differences in pathogenic mechanisms
employed by different infectious organisms. Given the effects
of CCR5 on such a broad range of pathogens, perhaps the
force that presumably drove CCR5⌬32 to its present frequency
in Caucasians was actually a diverse group of infectious diseases rather than a single, deadly pathogen.
CCR5 has been examined in one other study, involving an
HBV-infected Korean cohort that enrolled 377 individuals, of
whom 138 spontaneously recovered from infection (6).
CCR5⌬32 was absent from this cohort, but an association between the promoter variant CCR5⫺2459G, which might confer
lower promoter activity (23), and HBV recovery was reported.
This finding is consistent with a protective effect of lower
CCR5 levels, as is suggested in our study, although we did not
observe a protective effect of this variant in our study.
HIV coinfection in approximately 70% of our subjects was
carefully considered in our study, since CCR5⌬32 is known to
protect against AIDS progression. We conclude that the effect
of CCR5⌬32 on HIV infection cannot explain or confound the
effect of this allele on HBV clearance reported herein, for
several definitive reasons: (i) stratification of the analysis by
HIV status demonstrated an identical protective association of
CCR5⌬32 in HIV-negative and -positive subjects, (ii) those
with viral recovery and persistence were matched on HIV
status in our study, and (iii) HBV infection occurred prior to
HIV infection in nearly all cases, so the outcome of the viral
hepatitis infection was determined prior to acquiring HIV (19).
For those cases in which the HIV infection did occur first, it is
unlikely that immunosuppression from HIV played a significant role in the results since the HBV status was determined at
study entry, which is prior to profound HIV-induced immuno-
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